Navigation Links
BioMed Realty Trust Declares Third Quarter 2008 Common Stock and Preferred Stock Dividends
Date:9/15/2008

SAN DIEGO, Sept. 15 /PRNewswire-FirstCall/ -- BioMed Realty Trust, Inc. (NYSE: BMR) today announced that its board of directors has declared a third quarter 2008 dividend of $0.335 per share of common stock. The dividend is equivalent to an annualized dividend of $1.34 per common share.

BioMed also announced that its board of directors has declared a dividend of $0.46094 per share of the company's 7.375% Series A Cumulative Redeemable Preferred Stock for the period from July 16, 2008 through October 15, 2008.

The dividends are payable on October 15, 2008 to stockholders of record at the close of business on September 30, 2008.

About BioMed Realty Trust

BioMed Realty Trust, Inc. is a real estate investment trust (REIT) focused on Providing Real Estate to the Life Science Industry(R). The company's tenants primarily include biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry. BioMed Realty Trust owns or has interests in 69 properties, representing 112 buildings with approximately 10.4 million rentable square feet, including approximately 1.9 million square feet of development in progress. The company also owns undeveloped land parcels adjacent to existing properties that it estimates can support up to 1.4 million rentable square feet. The company's properties are located predominantly in the major U.S. life science markets of Boston, San Diego, San Francisco, Seattle, Maryland, Pennsylvania and New York/New Jersey, which have well-established reputations as centers for scientific research. Additional information is available at http://www.biomedrealty.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 based on current expectations, forecasts and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties include, without limitation: general risks affecting the real estate industry (including, without limitation, the inability to enter into or renew leases, dependence on tenants' financial condition, and competition from other developers, owners and operators of real estate); adverse economic or real estate developments in the life science industry or the company's target markets; risks associated with the availability and terms of financing and the use of debt to fund acquisitions and developments; failure to manage effectively the company's growth and expansion into new markets, or to complete or integrate acquisitions and developments successfully; risks and uncertainties affecting property development and construction; risks associated with downturns in the national and local economies, increases in interest rates, and volatility in the securities markets; potential liability for uninsured losses and environmental contamination; risks associated with the company's potential failure to qualify as a REIT under the Internal Revenue Code of 1986, as amended, and possible adverse changes in tax and environmental laws; and risks associated with the company's dependence on key personnel whose continued service is not guaranteed. For a further list and description of such risks and uncertainties, see the reports filed by the company with the Securities and Exchange Commission, including the company's most recent annual report on Form 10-K and quarterly reports on Form 10-Q. The company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE BioMed Realty Trust, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Johnson & Johnson Honors 2008 Recipients of The Dr. Paul Janssen Award for Biomedical Research
2. Plexus Systems, Inc. to Exhibit at BIOMEDevice Medical Technology Conference
3. Sinobiomed Retains CB Capital Partners as Financial Advisor to Maximize Shareholder Value
4. Regenesis Biomedical Announces Additions to Board of Directors
5. ArunA Biomedical Announces Exclusive Worldwide Technology Licensing Agreement to Commercialize Human Embryonic Stem Cell Derived Mesenchymal Cells
6. Vista Partners Updates Coverage on Inovio Biomedical Corporation (Amex: INO); $3.57 Price Target
7. ArunA Biomedical Names William T. Sharp President and Chief Executive Officer
8. Roche and Response Biomedical Corporation Aim to Reduce Vein-to-Brain Time with New Point-of-Care Cardiac Tests
9. Frontage Laboratories Completes Acquisition of Advanced Biomedical Research, Inc. (ABR)
10. Medicare Exemplary Provider Accreditation Awarded to Regenesis Biomedical
11. HIPAA Privacy Rule Impedes Biomedical Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... -- BERG, a biopharmaceutical company uncovering health solutions ... the appointment of Jason Haddock as ... brings to BERG over 20 years of experience ... financial functions at pharmaceutical companies, as well as ... Niven R. Narain , BERG,s Chief ...
(Date:2/8/2016)... Pa. , Feb. 8, 2016 Should ... standard bone cement products to prevent infection after standard ... that the experts at ECRI Institute have been fielding ... Infection or Fighting Your Bottom Line?" ... Your Bottom Line?" --> While ...
(Date:2/8/2016)... 8, 2016 Novan, Inc. today announced that Director ... of Directors of Novan. In addition, Robert Keegan has ... North Carolina . --> North Carolina ... it received a total of $32.8 million of net proceeds in ... investor network originating throughout the Research Triangle area of ...
(Date:2/8/2016)... ... February 08, 2016 , ... Information Management Services ( ... The upgrade represents a completely new technical foundation and is so significant it ... responsive design interface, significantly increased speed for search results, a streamlined layout and a ...
Breaking Biology Technology:
(Date:2/4/2016)... , Feb. 4, 2016 The ... apparently one of the most popular hubs of ... MetaHIT and other huge studies of human microbiota, ... past few years, the microbiome space has literally ... biomedical research. This report focuses on biomedical ...
(Date:2/3/2016)... Feb. 3, 2016 Vigilant Solutions announces today ... in Missouri solved two recent ... (LPR) data from Vigilant Solutions. Brian Wenberg ... which the victim was walking out of a convenience store and witnessed an ... to his vehicle, striking his vehicle and leaving the ...
(Date:2/2/2016)... Feb. 2, 2016 This BCC Research ... market by reviewing the recent advances in high ... drive the field forward. Includes forecast through 2019. ... the challenges and opportunities that exist in the ... solution developers, as well as IT and bioinformatics ...
Breaking Biology News(10 mins):